Logo image of DAWN

DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

NASDAQ:DAWN - US23954D1090 - Common Stock

7.2 USD
+0.22 (+3.15%)
Last: 8/22/2025, 8:01:47 PM
7.17 USD
-0.03 (-0.42%)
After Hours: 8/22/2025, 8:01:47 PM
Fundamental Rating

4

Taking everything into account, DAWN scores 4 out of 10 in our fundamental rating. DAWN was compared to 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DAWN as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, DAWN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DAWN has reported negative net income.
DAWN had a negative operating cash flow in the past year.
In the past 5 years DAWN always reported negative net income.
DAWN had a negative operating cash flow in each of the past 5 years.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.30%, DAWN is in the better half of the industry, outperforming 78.51% of the companies in the same industry.
Looking at the Return On Equity, with a value of -20.61%, DAWN belongs to the top of the industry, outperforming 84.70% of the companies in the same industry.
Industry RankSector Rank
ROA -18.3%
ROE -20.61%
ROIC N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

With an excellent Gross Margin value of 94.02%, DAWN belongs to the best of the industry, outperforming 93.99% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for DAWN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DAWN has more shares outstanding
DAWN has more shares outstanding than it did 5 years ago.
DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 6.61 indicates that DAWN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.61, DAWN is in the better half of the industry, outperforming 79.78% of the companies in the same industry.
DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.61
ROIC/WACCN/A
WACC9.73%
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

DAWN has a Current Ratio of 9.65. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
DAWN has a better Current ratio (9.65) than 80.15% of its industry peers.
DAWN has a Quick Ratio of 9.53. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 9.53, DAWN belongs to the best of the industry, outperforming 80.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.65
Quick Ratio 9.53
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.38% over the past year.
The Revenue has grown by 2190.50% in the past year. This is a very strong growth!
EPS 1Y (TTM)15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-480%
Revenue 1Y (TTM)2190.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%313.92%

3.2 Future

The Earnings Per Share is expected to grow by 24.09% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 36.00% on average over the next years. This is a very strong growth
EPS Next Y29.39%
EPS Next 2Y24.46%
EPS Next 3Y26.41%
EPS Next 5Y24.09%
Revenue Next Year18.13%
Revenue Next 2Y32.23%
Revenue Next 3Y38.26%
Revenue Next 5Y36%

3.3 Evolution

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DAWN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as DAWN's earnings are expected to grow with 26.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.46%
EPS Next 3Y26.41%

More info and screens

0

5. Dividend

5.1 Amount

DAWN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (8/22/2025, 8:01:47 PM)

After market: 7.17 -0.03 (-0.42%)

7.2

+0.22 (+3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-20 2025-10-20/bmo
Inst Owners94.54%
Inst Owner Change-9.79%
Ins Owners2.3%
Ins Owner Change0.3%
Market Cap737.50M
Analysts82.67
Price Target23.46 (225.83%)
Short Float %11.79%
Short Ratio5.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.39%
Min EPS beat(2)20.33%
Max EPS beat(2)22.45%
EPS beat(4)3
Avg EPS beat(4)-4.75%
Min EPS beat(4)-73.33%
Max EPS beat(4)22.45%
EPS beat(8)5
Avg EPS beat(8)9.07%
EPS beat(12)9
Avg EPS beat(12)6.89%
EPS beat(16)10
Avg EPS beat(16)1.6%
Revenue beat(2)0
Avg Revenue beat(2)-3.05%
Min Revenue beat(2)-5.83%
Max Revenue beat(2)-0.26%
Revenue beat(4)1
Avg Revenue beat(4)-4.88%
Min Revenue beat(4)-16.43%
Max Revenue beat(4)3.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.44%
PT rev (3m)-20.69%
EPS NQ rev (1m)13.29%
EPS NQ rev (3m)23.85%
EPS NY rev (1m)10.64%
EPS NY rev (3m)10.71%
Revenue NQ rev (1m)-3.39%
Revenue NQ rev (3m)-12.68%
Revenue NY rev (1m)-4.59%
Revenue NY rev (3m)-4.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.93
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.67
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS1.83
BVpS4.5
TBVpS4.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.3%
ROE -20.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.02%
FCFM N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 177.31%
Cap/Sales 3.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.65
Quick Ratio 9.53
Altman-Z 6.61
F-Score6
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)352.72%
Cap/Depr(5y)301.63%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-480%
EPS Next Y29.39%
EPS Next 2Y24.46%
EPS Next 3Y26.41%
EPS Next 5Y24.09%
Revenue 1Y (TTM)2190.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%313.92%
Revenue Next Year18.13%
Revenue Next 2Y32.23%
Revenue Next 3Y38.26%
Revenue Next 5Y36%
EBIT growth 1Y61.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.13%
EBIT Next 3Y24.46%
EBIT Next 5YN/A
FCF growth 1Y45.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.32%
OCF growth 3YN/A
OCF growth 5YN/A